Phase 1 trial of azer-cel reports good preliminary safety and efficacy
Physical, occupational and speech therapists will provide state-of-the-art outpatient care
Inconsistent regulation and limited toxicology tests present diagnostic and treatment challenges
Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advanced technologies are changing expectations about what’s possible
A rare opportunity to design for speed, care coordination, recovery and continuous monitoring
Multidisciplinary, proactive approach also improved discharge outcomes
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Therapists and physicians collaborate to get medically stable patients moving
Advertisement
Advertisement